Brief: Newbury Pharmaceuticals Reports Q3 EBITDA Of SEK -4 Mln
08/07/2026 07:09
BRIEF-Newbury Pharmaceuticals Reports Q3 EBITDA Of SEK -4 Mln July 8 (Reuters) - Newbury Pharmaceuticals AB NEWBRY.ST:
Q3 EBITDA SEK -4 MILLION
Q3 NET REVENUE SEK 8.9 MLN (6.7 MLN)
WE EXPECT FINAL QUARTER TO BENEFIT FROM ADDITIONAL PRODUCT LAUNCHES AND GROWING NUMBER OF PRODUCTS ACTIVE IN TENDERS
Source text: ID:nMFN7CgVYc
Further company coverage: NEWBRY.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Newbury Pharmaceuticals AB
See all newsBrief: Newbury Secures Hospital Portfolio Rights In Iraq
Brief: Newbury Signs Licence And Supply Deal For Guanfacine
Brief: Newbury Pharmaceuticals Gets Approval for Tofacitinib Newbury
Brief: Newbury Pharmaceuticals Secures Generic Approval For Dalbavancin Newbury
Brief: Newbury Pharmaceuticals Reports Q3 EBITDA Of SEK -4 Mln